CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Aclidinium bromide/formoterol fumarate dihydrate

Last Updated: February 24, 2015
Result type: Reports
Project Number: SR0423-000
Product Line: Reimbursement Review

Generic Name: Aclidinium bromide/formoterol fumarate dihydrate

Brand Name: Duaklir Genuair

Manufacturer: AstraZeneca Canada Inc.

Therapeutic Area: Chronic obstructive pulmonary disease

Indications: Chronic Obstructive Pulmonary Disease (COPD)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: September 18, 2015

Recommendation Type: List with clinical criteria and/or conditions